Oxaliplatin (L-OHP): a new reality in colorectal cancer.

Por Bleiberg, H.
Publicado em 1998

Adjuvant therapy in resectable gastric cancer.

Por Bleiberg, H., Gerard, B., Deguiral, P.
Publicado em 1992

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer p...

Por Bensmaïne, M A, Marty, M, Gramont, A de, Brienza, S, Lévi, F, Ducreux, M, François, E, Gamelin, E, Bleiberg, H, Cvitkovic, E
Publicado em 2001

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after...

Por Freyer, G, Rougier, P, Bugat, R, Droz, J-P, Marty, M, Bleiberg, H, Mignard, D, Awad, L, Herait, P, Culine, S, Trillet-Lenoir, V
Publicado em 2000

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado em 1997

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

Por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado em 2005

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

Por Primrose, J N, Bleiberg, H, Daniel, F, Belle, S Van, Mansi, J L, Seymour, M, Johnson, P W, Neoptolemos, J P, Baillet, M, Barker, K, Berrington, A, Brown, P D, Millar, A W, Lynch, K P
Publicado em 1999